Lista de obras -

210. NEURAPRO: A Multi-center RCT of Omega-3 Polyunsaturated Fatty Acids Versus Placebo in Young People at Ultra-High Risk of Psychotic Disorders: Medium-Term Outcome.

artículo científico publicado en 2017

22. The Effects of Antidepressant use on Clinical Outcomes in the NEURAPRO-E Trial.

artículo científico publicado en 2017

Adhesio interthalamica in individuals at high-risk for developing psychosis and patients with psychotic disorders

artículo científico publicado en 2008

Antibodies to Infectious Agents in Individuals at Ultra-High Risk for Psychosis

scientific article published on 03 January 2007

Caudate nucleus volume in individuals at ultra-high risk of psychosis: a cross-sectional magnetic resonance imaging study

artículo científico publicado en 2010

Chronic modulation of serotonergic neurotransmission with sertraline attenuates the loudness dependence of the auditory evoked potential in healthy participants

artículo científico publicado en 2011

Clinical trajectories in the ultra-high risk for psychosis population

artículo científico publicado en 2018

Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial

artículo científico publicado en 2020

Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people

artículo científico publicado en 2019

Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial

artículo científico publicado en 2020

Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?

artículo científico publicado en 2007

Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 y

artículo científico publicado en 2008

Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.

artículo científico publicado en 2016

F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS.

artículo científico publicado en 2018

Hippocampal volume reduction specific for later transition to psychosis or substance-associated effects?

artículo científico publicado en 2010

Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study

artículo científico publicado en 2009

Intervention in individuals at ultra-high risk for psychosis: a review and future directions

artículo científico publicado en 2009

NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.

artículo científico publicado en 2015

Neurobiological endophenotypes of psychosis and schizophrenia: are there biological markers of illness onset?

Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

artículo científico publicado en 2018

Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study.

artículo científico publicado en 2012

O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL.

artículo científico publicado en 2018

Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis

artículo científico publicado en 2020

Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis

artículo científico publicado en 2017

PACE: a specialised service for young people at risk of psychotic disorders.

artículo científico publicado en 2007

Pilot study evaluating the effect of massage therapy on stress, anxiety and aggression in a young adult psychiatric inpatient unit

artículo científico publicado en 2008

Pituitary volume increase during emerging psychosis.

artículo científico publicado en 2010

Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis

artículo científico publicado en 2005

Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population

scientific article published on 17 June 2020

Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals

artículo científico publicado en 2003

Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis

artículo científico publicado en 2012

Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis

artículo científico

Relational memory in first episode psychosis: implications for progressive hippocampal dysfunction after illness onset

artículo científico publicado en 2011

Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial.

artículo científico publicado en 2019

S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING.

artículo científico publicado en 2018

Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders

artículo científico publicado en 2006

Structural abnormalities in the cuneus associated with Herpes Simplex Virus (type 1) infection in people at ultra high risk of developing psychosis

artículo científico publicado en 2012

Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis

artículo científico publicado en 2007

Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia

artículo científico publicado en 2005

Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis

scientific article published on 09 October 2019

T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION.

artículo científico publicado en 2018

T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY.

artículo científico publicado en 2018

The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

artículo científico publicado en 2019

The effect of atypical antipsychotics on pituitary gland volume in patients with first-episode psychosis: a longitudinal MRI study

artículo científico publicado en 2010

The topical niacin sensitivity test: an inter- and intra-rater reliability study in healthy controls

artículo científico publicado en 2008

Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial

scientific article published on 21 November 2019

Vascular endothelial growth factor and brain-derived neurotrophic factor in quetiapine treated first-episode psychosis

artículo científico publicado en 2014

Ventricular volumes across stages of schizophrenia and other psychoses

artículo científico publicado en 2017

Lista de obras de

210. NEURAPRO: A Multi-center RCT of Omega-3 Polyunsaturated Fatty Acids Versus Placebo in Young People at Ultra-High Risk of Psychotic Disorders: Medium-Term Outcome.

22. The Effects of Antidepressant use on Clinical Outcomes in the NEURAPRO-E Trial.

Adhesio interthalamica in individuals at high-risk for developing psychosis and patients with psychotic disorders

Antibodies to Infectious Agents in Individuals at Ultra-High Risk for Psychosis

Caudate nucleus volume in individuals at ultra-high risk of psychosis: a cross-sectional magnetic resonance imaging study

Chronic modulation of serotonergic neurotransmission with sertraline attenuates the loudness dependence of the auditory evoked potential in healthy participants

Clinical trajectories in the ultra-high risk for psychosis population

Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial

Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people

Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial

Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?

Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 y

Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.

F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS.

Hippocampal volume reduction specific for later transition to psychosis or substance-associated effects?

Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study

Intervention in individuals at ultra-high risk for psychosis: a review and future directions

NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.

Neurobiological endophenotypes of psychosis and schizophrenia: are there biological markers of illness onset?

Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study.

O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL.

Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis

Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis

PACE: a specialised service for young people at risk of psychotic disorders.

Pilot study evaluating the effect of massage therapy on stress, anxiety and aggression in a young adult psychiatric inpatient unit

Pituitary volume increase during emerging psychosis.

Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis

Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population

Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals

Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis

Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis

Relational memory in first episode psychosis: implications for progressive hippocampal dysfunction after illness onset

Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial.

S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING.

Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders

Structural abnormalities in the cuneus associated with Herpes Simplex Virus (type 1) infection in people at ultra high risk of developing psychosis

Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis

Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia

Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis

T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION.

T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY.

The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

The effect of atypical antipsychotics on pituitary gland volume in patients with first-episode psychosis: a longitudinal MRI study

The topical niacin sensitivity test: an inter- and intra-rater reliability study in healthy controls

Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial

Vascular endothelial growth factor and brain-derived neurotrophic factor in quetiapine treated first-episode psychosis

Ventricular volumes across stages of schizophrenia and other psychoses